Implantation of cardiac monitor
DeviceIn patients with kryptogenic stroke, a cardiac monitor was implanted to detect atrial fibrillation
NCT Number: NCT02641678
Prospective mono-center diagnostic study determining potential discrepancies in identifying atrial fibrillation by intraindividually comparing different types of follow-up strategies:
1. How many stroke patients with atrial fibrillation are missed by standard stroke unit 24h- electrocardiography, and 2. what is the effectiveness of the extended invasive and non-invasive ECG analysis tools to detect atrial fibrillation in stroke patients?
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Atrial fibrillation often is paroxysmal and asymptomatic and, therefore, often not detected. Because atrial fibrillation is the leading risk factor for ischemic stroke, and oral anticoagulation is very efficacious for both primary and secondary stroke prevention in atrial fibrillation patients, detection of atrial fibrillation is essential to prevent stroke and stroke-induced disability and death. The incidence of atrial fibrillation and paroxysmal atrial fibrillation is particularly high in stroke patients. Short duration monitoring identified new atrial fibrillation in only about 5% to 10% of stroke patients. Estimates of missed paroxysmal atrial fibrillation in stroke patients go up to 40 000 patients in Germany per year.
Due to the known poor sensitivity of a 24h-ECG, all patients with stroke of unknown cause will undergo the above mentioned non-invasive and invasive ECG monitoring. Based on the data of these extended ECG-analyses, the rate of missed AF in conventionally diagnosed stroke unit patients could be determined by comparison to the 24h-ECG results. Additionally, a cost-benefit equation of the different ECG analysis tools will be calculated by comparison of the respective detection rates and the known follow-up costs.
Inclusion criteria
Patients years with acute ischemic stroke of unknown cause, monitored on a stroke unit undergoing routine diagnostic procedures (conventional 12-lead-ECG, 24h-ECG, echocardiography, cranial computed tomography or cranial magnetic resonance tomography, Transcranial Doppler and carotid duplex ultrasound, long-term blood pressure monitoring, standard laboratory investigations) Exclusion criteria: Stroke with known etiology, Stroke caused by intracranial hemorrhage
Diagnosis-as-usual:
Investigational measure:
Non-invasive:
Invasive:
Duration of measures per patient:
2 weeks hospitalization, ~1 month rehabilitation, then implantation of the ECG device, and 6 months follow-up: 7.5 months in total
Primary outcome:
To determine the prevalence of undiagnosed AF in stroke patients undergoing the diagnostic standard (24h-ECG)
Secondary outcome:
Effectivity and cost-effectiveness ratios of the different ECG analyis tools
Description of the outcome:
Based on the obtained data, the prevalence of undiagnosed atrial fibrillation in stroke patients whom atrial fibrillation is missed by the standard diagnostic procedure (24h-ECG) will be determined by different extensive non-invasive and invasive ECG monitoring tools.
Additionally, following values of the applied ECG analysis tools will be calculated and compared:
Safety:
The implantable direct cardiac rhythm monitor device is an established and widely used diagnostic procedure in patients with unexplained syncope.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients years with acute ischemic stroke of unknown cause, monitored on a stroke unit undergoing routine diagnostic procedures (conventional 12-lead-ECG, 24h-ECG, echocardiography, cCT or cMRI, Transcranial Doppler and carotid duplex ultrasound, long-term blood pressure monitoring, standard laboratory investigations)
Exclusion criteria
In patients with kryptogenic stroke, a cardiac monitor was implanted to detect atrial fibrillation
Time frame: 7.5 months
Based on the obtained data, the prevalence (in percent) of undiagnosed AF in stroke patients whom AF is missed by the standard diagnostic procedure (24h-ECG) will be determined by different extensive non-invasive and invasive ECG monitoring tools
Time frame: 7.5 months
The Sensitivity (in percent), the Specificity (in percent), the positive predictive value (in percent) and the negative predictive value (in percent) will be calculated for the automated ECG software analysis in comparison to the "gold-standard" the implanted cardiac monitor
Time frame: 7.5 months
The Sensitivity (in percent), the Specificity (in percent), the positive predictive value (in percent) and the negative predictive value (in percent) will be calculated for the automated ECG software analysis in comparison to the actual diagnostic standard the routinely performed ECG+longterm ECG.
Time frame: 7.5 months
The data can be helpful to increase the cost efficacy. There are 3 hypotheses. 1.) The software analysis is reliable enough to detect AF than an implantable device is no longer needed.
2.) The software analysis is unreliable 3.) The software analysis has a high negative predictive value and can provide as a preselection tool. Patients with probable AF calculated by the software analysis have a higher profit by the implantation than the patient with no AF calculated by the software.
University Hospital Muenster
Other
Acronym: TRACK-AF
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05820295
Arrhythmias, Cardiac, Atrial Fibrillation
New York, United States
View Trial DetailsNCT03702582
Arrhythmias, Cardiac, Atrial Fibrillation
Boston, Massachusetts, United States
View Trial DetailsNCT04907825
Arrhythmias, Cardiac, Atrial Fibrillation
Los Angeles, California, United States
View Trial DetailsNCT04769310
Arrhythmias, Cardiac, Atrial Fibrillation
New Orleans, Louisiana, United States
View Trial Details